Drug regulator halts obeticholic acid production, orders recall
LiveMint

The DCGI ordered the halt in production and recall of obeticholic acid tablets following similar global regulatory actions.
The DCGI has sought the cancellation of manufacturing licences for obeticholic
acid (5mg and 10mg tablets), used to treat primary biliary cholangitis (PBC),
following similar actions by the US FDA and the European Medicines Agency.





